Cargando…
Lipoxin A4 and its analog suppress inflammation by modulating HMGB1 translocation and expression in psoriasis
Psoriasis is a chronic inflammatory skin disease that affects 2–3% of the global population, and there is still no known possibility of a cure. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. BML-111 (5(S)-6(R...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541073/ https://www.ncbi.nlm.nih.gov/pubmed/28769106 http://dx.doi.org/10.1038/s41598-017-07485-1 |